Chimerix Inc (NASDAQ:CMRX) has been assigned a consensus rating of “Hold” from the six ratings firms that are covering the firm, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a sell recommendation, two have issued a hold recommendation and one has given a buy recommendation to the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $7.67.
Several analysts have recently commented on the stock. ValuEngine lowered shares of Chimerix from a “sell” rating to a “strong sell” rating in a research report on Thursday, November 9th. Zacks Investment Research raised shares of Chimerix from a “hold” rating to a “buy” rating and set a $5.25 price target on the stock in a research report on Friday, November 10th. HC Wainwright assumed coverage on shares of Chimerix in a research report on Friday, February 2nd. They set a “buy” rating and a $10.00 price target on the stock. Finally, JPMorgan Chase & Co. lowered shares of Chimerix from a “neutral” rating to an “underweight” rating in a research report on Wednesday.
In other news, insider Linda M. Richardson sold 19,833 shares of Chimerix stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $4.47, for a total transaction of $88,653.51. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 4.40% of the stock is currently owned by insiders.
Chimerix (CMRX) opened at $4.93 on Wednesday. Chimerix has a 12 month low of $4.17 and a 12 month high of $6.64. The firm has a market cap of $229.98, a P/E ratio of -3.45 and a beta of 1.42.
WARNING: This article was first published by American Banking News and is the property of of American Banking News. If you are accessing this article on another website, it was illegally copied and reposted in violation of U.S. and international trademark & copyright legislation. The correct version of this article can be viewed at https://www.americanbankingnews.com/2018/02/14/chimerix-inc-cmrx-receives-average-recommendation-of-hold-from-brokerages.html.
Chimerix Company Profile
Chimerix, Inc is a biotechnology company. The Company is focused on discovering, developing and commercializing medicines that address unmet medical needs. Its lead compound, brincidofovir, is in development as an oral and intravenous (IV) formulation for the prevention and treatment of deoxyribonucleic acid (DNA) viruses, including smallpox, adenoviruses (AdV), and the human herpesviruses.
Receive News & Ratings for Chimerix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix and related companies with MarketBeat.com's FREE daily email newsletter.